The evidence behind oral semaglutide

Which products have been studied

When you read that oral semaglutide "works," it matters which product the evidence came from. Two approved tablets have their own randomized, placebo-controlled research. A compounded capsule, even with the same active ingredient, is a different product with no published trial data.

The distinction is not a technicality. With an oral peptide, the formulation largely determines how much drug reaches your bloodstream, and therefore how much effect you can expect.

Rybelsus in type 2 diabetes

Rybelsus was studied in adults with type 2 diabetes, where the main goal was lowering blood sugar. It is approved as an add-on to diet and exercise for that purpose. Gastrointestinal effects such as nausea, vomiting, diarrhea, indigestion and constipation were common, affecting roughly 30% to 50% of patients in reports summarized by the American Academy of Family Physicians, and 8% to 16% stopped in trials because of side effects.

Weight loss was a secondary effect. In one 26-week comparison summarized by AAFP, a daily 10 mg oral dose produced an average loss of about 4.8 kg, compared with about 6.4 kg on a weekly 1 mg injection. Those doses are lower than the ones now used for weight management.

Wegovy tablets for weight management

The weight-management tablet was tested at 25 mg once daily in adults with obesity, or overweight plus at least one weight-related condition, for up to 64 weeks, followed by a period off the drug. The results were published in the New England Journal of Medicine in 2025 and led to FDA approval for long-term weight reduction.

The Wegovy label also lists cardiovascular risk reduction for the tablet in adults with established heart disease and excess weight. The large heart outcomes trial behind that indication, SELECT, used the weekly injection.

Why adherence shapes the results

Trial participants followed precise instructions: one tablet each morning on an empty stomach, with no more than 4 ounces of plain water, then at least 30 minutes before any food, drink or other pills. In daily life, coffee too soon, a missed wait or taking the tablet with other morning medicines can reduce absorption.

That is one reason results in routine care may be less consistent than in trials. If a tablet seems to stop working, the first question is usually about the routine, not the dose.

What the trials cannot tell you

• How compounded capsules perform. They use different formulations and have not been studied.
• How a capsule dose compares with an approved tablet or an injection. There is no validated conversion.
• Long-term effects beyond the trial period, which for weight trials is typically one to one and a half years.
• How the tablets work in groups that were few in the trials, such as people over 75.

How to read claims you see online

Marketing for oral GLP-1s often borrows numbers from injection trials or from the approved tablet and attaches them to a different product. Before trusting a figure, ask three things: which exact product was tested, at what dose, and for how long. If the answer is an injection or a branded tablet, the number describes that product, not a compounded capsule.

Also check whether a result describes everyone who started the trial or only those who kept taking the drug as directed. Results limited to people who stayed on treatment are usually larger, and both views are useful when you are setting expectations.

Compounded capsules: our position

HealifyMD prescribes compounded semaglutide capsules only when a clinician believes they are appropriate for you. They are made by a licensed U.S. pharmacy, are not FDA-approved, have not been reviewed by the FDA for safety, effectiveness or quality and are not equivalent to Rybelsus or Wegovy tablets. The FDA has also reported adverse events tied to compounded semaglutide more broadly, including dosing errors.

Because the evidence gap is real, your clinician will track your weight, side effects and, where relevant, blood sugar, and will discuss switching to an approved tablet or an injection if your response is weak. Compounded oral semaglutide is $299/month, confirmed at the eligibility review.

Safety findings that apply to all versions

Semaglutide's label carries a boxed warning about thyroid C-cell tumors in rodents; it is not used by anyone with a personal or family history of medullary thyroid carcinoma or with MEN 2. Other warnings include pancreatitis, gallbladder disease, kidney injury from dehydration and low blood sugar with insulin or sulfonylureas. The tablets can raise levothyroxine levels. Semaglutide is not for use in pregnancy.